Kerala Government Faces Criticism and Defense Over SMA Drug Controversy
The Kerala government faces criticism over the distribution of a drug for children with spinal muscular atrophy (SMA), with CPI(M) accusing the Health Minister K. Muraleedharan and the Congress-led UDF of following privatization and corporate interests. Muraleedharan defended the drug's quality, stating its withdrawal was to address media concerns and emphasized expert committee decisions. He also suggested opposition from pharmaceutical companies producing imported medicines. The controversy includes questions about drug trials, quality checks, and government transparency.
First-hand measurement across 2 sources
We measured how 2 outlets covered this story. Coverage leans centre-right overall (Left 10%, Centre 44%, Right 46%). Overall sentiment is neutral (45/100). Lens Score 66/100.
Outlets measured: theprint, thehindu. See how each one headlined and framed the same story in the source comparison below.
AI Analysis
All 2 outlets scored close to centre on political lean. The real divergence here is in emphasis, not lean — compare the headlines below to see how each outlet chose to frame the same facts.
Sentiment was consistent across outlets (35–55/100), indicating broadly factual reporting rather than editorialising.
Coverage timeline
thehindu broke this story on 23 Oct, 03:52 pm. Other outlets followed.